arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Friday 23 September

Please find below the programme schedule for Friday 23 September 2022.

Print program

Friday 23 Sep

Meet the experts session 2

08:00

Suite No. 292 (Ruby) | M2.1 Point of care test

Cornelia Lass Flörl, Austria and Martin Hönigl, Austria

08:00

Suite No. 293 (Sapphire) | M2.2 Allergic fungal lung diseases

Ritesh Agarwal, India and Koichiro Asano, Japan

09:00

Conference hall B | Key note (P6) New azoles in management of invasive mould infections

Johan Maertens, Belgium

Parallel session 7

Parallel session 7 will take place from 10:30 AM - 12:00 PM and consists of five symposia.

Conference hall B | S7.1 Update in management of fungal infection in adult haematology

Chairs: Xiao-Jun Huang, China and Subhash Varma, India

10:30

S7.1a TBD

10:50

S7.1b Breakthrough fungal infection

Dinesh Bhurani, India

11:10

S7.1c New treatment options for management of fungal infections

Johan Maertens, Belgium

11:30

S7.1d* Reliability of bedside point-of-care tests for C. neoformans, M. tuberculosis and S. pneumoniae in adults living with HIV presenting with suspected central nervous system infection (CNS) in low- and middle-income settings: Preliminary results from the DREAMM study

Aude Sturny Leclere, France

11:45

Q&A with all speakers

Conference hall A | S7.2 More than just candidemia: Clinical aspects, diagnosis and treatment, and pathogenesis of deep- seated candidiasis

Chair: Malini Capoor, India

10:30

S7.2a Non- bloodstream deep-seated candidiasis: Clinical spectrum of disease, epidemiology and antifungal resistance

M. Hong Nguyen, USA

10:50

S7.2b Advances in the diagnosis, treatment and prevention of deep-seated candidiasis

Ram Gopalakrishnan, India

11:10

S7.2c Candida- host interactions and pathogenesis of deep-seated candidiasis, and lessons for patient management

Neil Clancy, USA

11:30

S7.2d TBD

11:45

Q&A with all speakers

Suite No. 292 (Ruby) | S7.3 Emergent theories on pathogenic fungal dispersal around the globe

Chairs: Jianping Xu, Canada and Anuradha Chowdhary, India

10:30

S7.3a Emergence and dispersal of Coccidioides in the Western Hemisphere

David Engelthaler, USA

10:50

S7.3b Niche and dispersal of Candida auris

Wieland Meyer, Australia

11:10

S7.3c Evolution of Pseudogymnoascus destructans, the cause of white nose syndrome in bats

Jianping Xu, Canada

11:30

S7.3d* Nuclear Magnetic Resonance based identification of metabolites in Dermatophytes

Vikramjeet Singh, India

11:45

Q&A with all speakers

Suite No. 293 (Sapphire) | S7.4 Pathgenesis and host defense

Chairs: Shibuya Kazutoshi, Japan and Shigeru Kohno, Japan

10:30

S7.4a Vaccine-inducing lung resident CD4+ memory T cells are protective against Cryptococcus gattii infections

Keigo Ueno, Japan

10:50

S7.4b Microaerobic conditions enhance fungal pathogenesis in Candida spp.

Yoshitsugu Miyazaki, Japan

11:10

S7.4c The hidden pathophysiology behind the images of invasive fungal infections

Kazutoshi Shibuya, Japan

11:30

S7.4d* Candida albicans SR-like protein kinases regulate different cellular processes: Sky1 is involved in control of ion homeostasis, while Sky2 is important for dipeptide utilization

Philipp Brandt, Germany

11:45

Q&A with all speakers

Suite No. 294 (Emerald) |S7.5 MMCR case report session

Chairs: Adilia Warris, UK and Rajeev Soman, India

10:30

1. Human protothecosis: a case report in Northeastern Brazil

Conceicao Pedrozo, Brazil

10:40

2. Basidiobolus meristosporus - A new species on the block!

Ruchita Chabra, India

10:50

3. A Psittacine bite and subcutaneous Zygomycosis in immune competent: Case with therapeutic challenge

Shivani Choubey, India

11:00

4. An unusual recurrent case of Cryptococcal sacroilitis in an immunocompetent elderly female in Rajasthan, India

Sidhya Choudhary, India.

11:10

5. Paratracheal abscess by plant fungus Chondrostereum purpureum. First case report of human infection

Soma Dutta, India

11:20

6. Parinaud’s Oculoglandular Syndrome as an atypical manifestation of sporotrichosis in Brazil

Filipe Batista, Brazil

11:30

7. Lodderomyces elongisporus fungemia in a late post-operative patient with ventricular septal defect: case report

Sudesh Gourav, India

11:40

8. First case of cutaneous mycosis caused by Nannizziopsis sp. in Chelonia

Giorgia Matteucci, Italy

11:50

Q&A with all speakers

12:00

Lunch and poster session 3

Conference Hall C - Exhibition

Conference hall B | Sponsored symposium 3: Pipeline session

Chairs: Rajeev Soman, India / Alessandro C. Pasqualotto, Brazil

12:30

Olorofim – first of a novel class of antifungals

Johan Maertens, Belgium

12:45

Opelconazole (PC945): A Novel Inhaled Azole in Late-Stage Clinical Development for Invasive Pulmonary Aspergillosis

Dr. Lance Berman, MB.ChB; M.S. (Pharm. Med.) Chief Medical Officer, Pulmocide Ltd

Invasive aspergillosis (IA) occurs in 4% of patients undergoing remission induction chemotherapy for hematological malignancies, in 9% of allogeneic hematological stem cell transplant recipients [Van de Peppel 2018] and in 2-8% of lung transplant recipients [Samanta 2020, Baker 2020, Ullmann 2018], despite the use of antifungal prophylaxis in these patient groups. Aspergillus is a particularly important opportunistic infection in lung transplant recipients [Pasupneti 2017, Husain 2019] with invasive disease occurring in 2-8% of patients in the first-year post-transplant [Samanta 2020, Baker 2020, Ullmann 2018].

Currently available antifungal therapies have treatment-limiting side effects including drug-drug interactions [Ullmann 2018, Husain 2016]. These pose a significant challenge in patients with an underlying malignancy or in recipients of a solid organ transplant. In lung transplant recipients the anastomotic site is particularly vulnerable due to disruption of blood supply and the presence of sutures [Cho, 2015]. Even with systemic antifungals, mortality rates remain high [Herbrecht, 2019].

There are therefore limited therapeutic options for patients with invasive pulmonary aspergillus disease particularly for those who do not respond to initial therapy or in whom antifungals that are approved for the treatment of invasive aspergillosis are contraindicated.

A potent, effective inhaled anti-fungal agent with prolonged lung tissue residence and minimal systemic update would be a valuable adjunct to current therapeutic options. To date, treatment using inhaled antifungal agents has been limited to repurposing available systemic medicines. PC945 (opelconazole) Nebulizer Suspension is a novel triazole antifungal agent which was specifically designed for inhaled use and which is being developed as an inhaled treatment for pulmonary fungal disease. The profile of opelconazole has been assessed in a range of in vitro and in vivo studies demonstrating that it has potent antifungal activity against A. fumigatus, C. albicans and a range of other fungi [Colley T et al., 2017; Colley et al., 2019]. Following inhaled delivery, local concentrations of opelconazole in the lung are high, while systemic bioavailability is minimal [Cass et al., 2020]. This profile could allow opelconazole to provide effective antifungal activity in the respiratory tract while limiting the potential for systemic side effects.

Opelconazole has been supplied to patients with serious or life-threatening pulmonary aspergillosis who have not responded to available mold-active therapies under a Special Needs program regulated in the United Kingdom by the Medicines and Healthcare products Regulatory Agency. Successful outcomes in the first two patients who developed invasive pulmonary aspergillosis due to infections with A. fumigatus complex shortly after lung transplantation have been reported [Pagani 2020]. Available data from the program, in this non-clinical trial setting, indicate that opelconazole was generally well tolerated with no drug-drug interactions reported in the 11 patients who received opelconazole as treatment and in the 12th patient who received it as prophylaxis. Favorable responses at 3 months were observed in 9 out of the 11 patients who received opelconazole as treatment.

13:00

Ibrexafungerp: First in a New Class Triterpenoid Antifungal in Development for Treatment of Invasive Fungal Infections and Vulvovaginal Candidiasis

Nkechi Azie, MD, MBA, FIDSA, Vice President, Head Clinical Development and Medical Affairs, Scynexis

13:15

Q&A with all speakers

14:00

Conference hall B | Key note (P7): Banging our head against the (fungal) wall

Neil Gow, UK

Parallel sessions 8

Parallel session 8 will take place from 03:00 - 05:30 PM and consists of five symposia.

Conference hall B | S8.1 Tackling Candida auris in resource-limited settings

Chairs: Nelesh Govender, South-Africa and Methee Chayakulkeeree, Thailand

15:00

S8.1a Something along the lines of “A global update on Candida auris’

Tom Chiller, USA

15:20

S8.1b Emergence and establishment of C. auris in Indian hospitals

Anuradha Chowdhary, India

15:40

S8.1c Is a search and destroy strategy still feasible for Candida auris in South Africa?

Nelesh Govender, South-Africa

16:00

S8.1d* Innovative approaches to tackle C. auris in Latin America

Arnaldo Lopes Colombo, Brazil

16:15

Q&A with all speakers

Conference hall A | S8.2 What is new in pediatric mycology?

Chairs: Emmanuel Roilides, Greece and Tanu Singhal, India

15:00

S8.2a Trends in epidemiology of pediatric Candida infections worldwide

Emmanuel Roilides, Greece

15:20

S8.2b Aspergillus spp. in primary immunodeficiencies and cystic fibrosis

Adilia Warris, UK

15:40

S8.2c Updated guidelines in the management invasive fungal infections in paediatrics

Andreas Groll, Germany

16:00

S8.2d* Fungal beta-glucans and mannan performances in HIV-associated histoplasmosis

Antoine Adenis, France

16:15

Q&A with all speakers

Suite No. 292 (Ruby) | S8.3 How the Fungal Cell Wall Glycan Can Modulate the Immune Response?

Chairs: Boualem Sendid, France and Rajendra Prasad, India

15:00

S8.3a Structural aspects

Thierry Fontaine, France

15:20

S8.3b How Fungal Cell Wall Glycans Modulate the Activation of Platelets?

Samir Jawhara, France

15:40

S8.3c Cell wall glycans as targets for the development of new antifungals

Vishukumar Aimanianda, France

16:00

S8.3d* Characterization of glycosylphosphatidylinositol-linked aspartyl proteases in Candida glabrata: role in pathogenicity

Rupinder Kaur, India

16:15

Q&A with all speakers

Suite No. 293 (Sapphire) | S8.4 Veterinary Mycology and One Health Working Group Business Meeting

Chairs : Jacques Guillot, France and Amir Seyedmousavi, USA

S8.5 Genotyping of Cryptococcus neoformans and C. gattii

Chairs: Wieland Meyer, Australia and Carolina Firacative, Colombia

15:00

S8.5a The global MLST database and it use in characterising the population structure of the Cryptococcus neoformans and C. gattii species complexes

Wieland Meyer, Australia

15:20

S8.5b Molecular Epidemiology of the C. neoformans and C. gattii species complexes in India

Ferry Hagen, Netherlands

15:40

S8.5c MLST Genotyping and phylogenetics of AD-hybrids

Massimo Cogliati, Italy

16:00

S8.5d* Cryptococcus neoformans and Cryptococcus gattii clinical isolates from Colombia develop heteroresistance to fluconazole at high concentrations

Carolina Firacative, Colombia

16:15

Q&A with all speakers

16:30

Break

Conference hall C - Exhibition

Parallel session 9

Parallel session 9 will take place from 04:45 - 06:15 PM and consists of five symposia.

Conference hall B | S9.1 Chronic Pulmonary Aspergillosis - where do we stand?

Chair: Inder Paul Singh, India

16:45

S9.1a Diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis

Malcolm Ricardson, UK

17:05

S9.1b TBD

17:25

S9.1c Current treatment options for CPA and future directions

David Denning, UK

17:45

S9.1d* Chronic pulmonary aspergillosis in post-tb and retreatment tb patients in Lagos, Nigeria

Adeyinka Davies, Nigeria

18:00

Q&A with all speakers

Conference hall A | S9.2 Azole resistance in Aspergillus fumiagatus: how hot is your hotspot?

Chairs: Jacques Meis, Netherlands / Katrien Lagrou, Belgium

16:45

S9.2a Hotspots of AMR in A. fumigatus; sex, drugs & (re) evolution

Harsimran Kaur, India

17:05

S9.2b Hot and Cold: the expanding distribution of triazole-resistance in Aspergillus fumigatus

Jianping Xu, Canada

17:25

S9.2c The potential role of the environment in azole-resistant veterinary A. fumigatus isolates – Penguin in the coalmine?”

Hanne Debergh, Belgium

17:45

S9.2d* Directed evolution of voriconazole resistance in Aspergillus fumigatus identifies novel mutations responsible for triazole resistance

Nir Osherov, Israel

18:00

Q&A with all speakers

Suite No. 292 (Ruby) | S9.3 Drug resistance in emerging pathogenic fungi

Chairs: Rajendra Prasad, India and Kaustuv Sanyal, India

16:45

S9.3a Antifungal resistance in emerging Candida auris

Jeffrey Rybak, Germany

17:05

S9.3b Fighting drug resistance with immunotherapies: Update on the Candida vaccine project

Ashraf Ibrahim, USA

17:25

S9.3c Antifungal drug resistance in clinical isolates of Candida spp: behind the curtains

Dominique Sanglard, France

17:45

S9.3d* Antivirulence drug discovery to disarm Candida albicans with metabolites from myxobacteria

Raghav Vij, Germany

18:00

Q&A with all speakers

Suite No. 293 (Sapphire) | S9.4 Free oral paper session

Chairs: Vijaylata Rastogi, India and Kaustav Sanyal, India

16:45

S9.4a* Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: antifungal susceptibility and clinical outcome

Sanchita Mitra, India

17:05

S9.4b* Trimetallic Cu-Zn-Fe nanoparticles induced apoptosis and cell cycle arrest in multidrug-resistant Candida auris

Hamad Alam, South Africa

17:25

S9.4c* TBD

17:45

S9.4d* Aspergillus fumigatus complicates one third of the patients with suspected bronchial asthma or pulmonary tuberculosis: clinical validation of indigenously developed diagnostic kits

Taruna Madan, India

18:00

Q&A with all speakers

Suite No. 294 (Emerald) | S9.5 Malassezia: pathogenesis and disease

Chair: Shivaprakash Rudramurthy / Bansidhar Tarai, India

16:45

S9.5a Role of Malassezia in Crohns disease and IBD

Shivaprakash Rudramurthy, India

17:05

S9.5b The need for longitudinal testing in human disease

Jayanthi Savio, India

17:25

S9.5c Malassezia/Host interactions and the Il-17/23 axis

Salomé LeibundGut- Landmann, Switzerland

17:45

S9.5d* Genotyping of Malassezia species from seborrheic dermatitis/dandruff patients

Prasanna Honnavar, Antigua & Barbuda

18:00

Q&A with all speakers

19:30

Congress dinner

Sunday Nursery (buses will depart from the entrance of the Ashok at 07:00 PM)